Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 11 studies
Add to Evidence TrackerType 2 Diabetes (T2D)Supplements and Vitamins
Research Summary
Analyzed using Evidence Intelligence™
Pilot protocol compares Ayurvedic Nimba-Amalakyadi powder versus metformin for type 2 diabetes
Last updated May 26, 2026
Key finding
This article is a pilot trial protocol in adults with newly diagnosed type 2 diabetes that plans to compare Nimba-Amalakyadi powder against metformin over 45 days, with follow-up to day 90, and no final efficacy results are reported yet.
This publication describes a planned pilot randomized open-label trial, not completed efficacy outcomes. It proposes enrolling 36 participants with type 2 diabetes to compare Nimba-Amalakyadi powder versus metformin for 45 days, with day-90 follow-up. The protocol emphasizes feasibility metrics and exploratory glycemic trends, but final comparative results are not available in this article.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Low
Study type
Randomized Controlled Trials (RCTs)
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This article is a pilot trial protocol in adults with newly diagnosed type 2 diabetes that plans to compare Nimba-Amalakyadi powder against metformin over 45 days, with follow-up to day 90, and no final efficacy results are reported yet.
Published in
Journal Reference
Publication details and source links for this paper.
Sawarkar P, Sawarkar GR. Evaluation of the comparative efficacy of an Ayurvedic formulation (Nimba-Amalakyadi powder) vs metformin in the management of type 2 diabetes mellitus: protocol for a pilot study. JMIR Res Protoc. 2026;15:e63574. doi:10.2196/63574
Main Effects
No completed comparative efficacy results reported in this protocol publication
Planned glycemic endpoints include HbA1c, fasting blood sugar, postprandial glucose, and urine sugar
Feasibility endpoints include recruitment, retention, adherence, acceptability, and data completeness
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Metformin, Nimba-Amalakyadi powder and HbA1c, Fasting Plasma Glucose (FPG), Postprandial blood glucose, and 1 more.
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
- HbA1c
- Fasting Plasma Glucose (FPG)
- Postprandial blood glucose
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 54
3
Related topics
5
Evidence pairs
579
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Uses a randomized study design signal
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Metformin Therapies and HbA1c
Related evidence
Evidence topic
Glycemic Control
Save evidence
Evidence topic
HbA1c Reduction
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting Plasma Glucose (FPG)
Nimba-Amalakyadi powder → Fasting Plasma Glucose (FPG)
Nimba-Amalakyadi powder → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPostprandial blood glucose
Nimba-Amalakyadi powder → Postprandial blood glucose
Nimba-Amalakyadi powder → Postprandial blood glucose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Methods section specifies randomized allocation with two groups and 45-day intervention exposure plus day-90 follow-up.
- The paper explicitly identifies itself as a protocol and states final results are expected after completion phases.
- Outcome variables are described as planned measurements rather than reported comparative endpoint results.
Who this applies to
Adults aged 20-60 years with newly diagnosed type 2 diabetes (<6 months)
Keep in Mind
Interpret this as a protocol, not a completed efficacy trial.
Between the Lines
- This publication is a protocol and does not report final efficacy results.
- Small planned pilot sample size (n=36) limits inferential strength.
- Open-label design may introduce performance and expectation biases.
- Single-center setting may limit generalizability.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and HbA1c, Metformin Therapies and Fasting Glucose.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Metformin Therapies → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 11 studies
View evidenceMedications
Metformin Therapies → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
11 studies
intervention_hubContributes to Metformin Therapies evidence base.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
5 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and HbA1c
Intervention: MetforminOutcome: HbA1c
11 results
All studies on Metformin and Fasting Plasma Glucose (FPG)
Intervention: MetforminOutcome: Fasting Plasma Glucose (FPG)
5 results
All studies on Metformin
Intervention: Metformin
11 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
All studies measuring Fasting Plasma Glucose (FPG)
Outcome: Fasting Plasma Glucose (FPG)
5 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies improve HbA1c?
Strong Evidence
Metformin Therapies appears to improve HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.2 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Nimba-Amalakyadi powder improve fasting plasma glucose (fpg)?
Emerging Evidence
Nimba-Amalakyadi powder may improve Fasting Plasma Glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Nimba-Amalakyadi powder improve HbA1c?
Emerging Evidence
Nimba-Amalakyadi powder may improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Nimba-Amalakyadi powder improve postprandial blood glucose?
Emerging Evidence
Nimba-Amalakyadi powder may improve Postprandial blood glucose.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Postprandial blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Vildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesHRS-7535 improves glycemic control in adults with type 2 diabetesEarly use of effective therapies may improve diabetes outcomesPremeal metformin improves postmeal glucose control in diabetes.Tofogliflozin may improve insulin secretory capacity in some type 2 diabetes patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.